Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

J Infect Dis · 2018 · PMC5913599 · PMID 29401325

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Exploratory analyses showed a trend for higher reactogenicity in the 60RSV-PreF-Al group, compared with the nonadjuvanted RSV-PreF groups, without evidence of an immunological benefit of the adjuvant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.